The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Analyzing Responses to 177LuPSMA-617 in Patients With Metastatic CRPC

Jeremie Calais, MD
Published Online:6:46 PM, Fri May 24, 2019


Jeremie Calais, MD, assistant clinical professor, Department of Nuclear Medicine, Ahmanson Translational Imaging Division, discusses the results from a preliminary analysis of a phase II trial investigating 177 lutetium prostate-specific membrane antigen-617 (177LuPSMA-617) in patients with metastatic castration-resistant prostate cancer.

Prostate-specific antigen (PSA) levels, which was the primary endpoint of the study, declined by at least 50% after 2 cycles of therapy. This seems early, Calais says, but the retrospective analysis data appeared promising.

Overall, close to 30% of patients had PSA levels decline by at least 50% after 2 cycles of therapy. However, the best response overall was 40% across all number of cycles. Among these responders, the best response was achieved after 3 cycles, Calais concludes.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.